SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alkem Laboratories - Quaterly Results

29 May 2024 Evaluate
The revenue zoomed 5.69% to Rs. 23653.70 millions for the quarter ended March 2024 as compared to Rs. 22379.90 millions during the corresponding quarter last year.Good  Net Profit growth of 27.54% reported above the corresponding previous quarter figure of Rs. 2547.90 millions to Rs. 3249.70 millioins.Operating profit surged to 4913.10 millions from the corresponding previous quarter of 4085.90 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 23653.70 22379.90 5.69 97477.20 90545.50 7.66 97477.20 90545.50 7.66
Other Income 837.90 766.00 9.39 3059.90 2662.90 14.91 3059.90 2662.90 14.91
PBIDT 4913.10 4085.90 20.25 22711.20 16432.40 38.21 22711.20 16432.40 38.21
Interest 206.80 217.40 -4.88 819.10 864.00 -5.20 819.10 864.00 -5.20
PBDT 4581.10 3868.50 18.42 21253.80 15568.40 36.52 21253.80 15568.40 36.52
Depreciation 691.00 571.60 20.89 2443.50 2298.50 6.31 2443.50 2298.50 6.31
PBT 3890.10 3296.90 17.99 18810.30 13269.90 41.75 18810.30 13269.90 41.75
TAX 640.40 749.00 -14.50 1338.80 1925.20 -30.46 1338.80 1925.20 -30.46
Deferred Tax -133.70 212.70 -162.86 -1994.00 -350.00 469.71 -1994.00 -350.00 469.71
PAT 3249.70 2547.90 27.54 17471.50 11344.70 54.01 17471.50 11344.70 54.01
Equity 239.10 239.10 0.00 239.10 239.10 0.00 239.10 239.10 0.00
PBIDTM(%) 20.77 18.26 13.77 23.30 18.15 28.38 23.30 18.15 28.38

Alkem Laboratories Share Price

5583.70 16.00 (0.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×